Ronald de Wit

Low Incidence of Anti-Interferon-Alpha Antibodies in Patients Treated with Interferon-Alpha-2A for AIDS-Associated Kaposi's Sarcoma

R. de Wit, S. Danner, P. Bakker, 1990, International journal of STD & AIDS.

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

J. Bono, B. Tombal, C. Sternberg, 2021 .

Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

R. Berger, J. Bono, E. Antonarakis, 2019, Journal of Clinical Oncology.

Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

J. Carles, J. Bono, B. Tombal, 2020 .

Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.

D. Bajorin, H. Nishiyama, A. Balar, 2020 .

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

T. Powles, E. Plimack, D. Bajorin, 2021 .